Clinical Trial Update: Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) [Phase 2]

View source ↗

Summary

Phase 2 trial update on daprodustat for anemia in chronic kidney disease shows completed study with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• Daprodustat (daprodustat)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anaemia | Phase 2 | Status: COMPLETED | Results posted: 2021-06-03